尽管局限性前列腺癌的 5 年生存率接近 100%，但转移性前列腺癌的生存率显着下降至 32%。因此，确定反映从局部疾病进展为转移性前列腺癌的分子指标至关重要。为了寻找与前列腺癌转移相关的分​​子指标，我们对转移性前列腺癌的快速尸检组织样本进行了蛋白质组学分析（N = 8）和局限性前列腺癌（N = 2）。然后，我们利用多个独立、公开的前列腺癌患者数据集来选择也与较差的前列腺癌临床预后相关的候选者。通过蛋白质组学分析，我们鉴定了 154 种在转移灶中相对于局限性前列腺癌表达增加的蛋白质。从这些与前列腺癌复发 (N = 28) 和较短无病生存期 (N = 37) 相关的候选者子集中，我们确定了一个 5 基因特征组，其在预测较差临床预后方面的性能优于个体候选者。我们的研究提出了一个新的 5 基因特征组，该组与较差的临床预后相关，并且在前列腺癌转移中蛋白质和 mRNA 水平均升高。我们的 5 基因特征面板代表了预测前列腺癌进展至转移的潜在模式。© 2024。作者。

Despite nearly 100% 5-year survival for localised prostate cancer, the survival rate for metastatic prostate cancer significantly declines to 32%. Thus, it is crucial to identify molecular indicators that reflect the progression from localised disease to metastatic prostate cancer.To search for molecular indicators associated with prostate cancer metastasis, we performed proteomic analysis of rapid autopsy tissue samples from metastatic prostate cancer (N = 8) and localised prostate cancer (N = 2). Then, we utilised multiple independent, publicly available prostate cancer patient datasets to select candidates that also correlate with worse prostate cancer clinical prognosis.We identified 154 proteins with increased expressions in metastases relative to localised prostate cancer through proteomic analysis. From the subset of these candidates that correlate with prostate cancer recurrence (N = 28) and shorter disease-free survival (N = 37), we identified a 5-gene signature panel with improved performance in predicting worse clinical prognosis relative to individual candidates.Our study presents a new 5-gene signature panel that is associated with worse clinical prognosis and is elevated in prostate cancer metastasis on both protein and mRNA levels. Our 5-gene signature panel represents a potential modality for the prediction of prostate cancer progression towards the onset of metastasis.© 2024. The Author(s).